Adalimumab is a biologic medication used to treat several inflammatory and autoimmune conditions. It belongs to a class of medicines called tumor necrosis factor inhibitors, which help reduce inflammation by blocking a specific immune system protein. Understanding its uses, administration, potential side effects, and safety precautions helps patients make informed decisions with healthcare professionals.
Adalimumab is a prescription medicine that helps control inflammation associated with certain autoimmune diseases. It is commonly administered as an injection under the skin and may be prescribed when a healthcare professional determines that its benefits outweigh its potential risks. Treatment plans vary according to the condition being treated, the patient's age, and other medical considerations.
Adalimumab works by blocking tumor necrosis factor alpha, or TNF alpha, a protein involved in inflammatory responses. Excessive activity of this protein can contribute to inflammation and tissue damage in certain conditions. By inhibiting TNF alpha, adalimumab may help reduce symptoms and improve disease control.
Depending on the specific product approval and patient eligibility, adalimumab may be prescribed for several conditions.
Rheumatoid arthritis: Helps reduce joint inflammation, pain, stiffness, and the risk of progressive joint damage.
Psoriatic arthritis: Helps manage joint inflammation and associated symptoms in people with this inflammatory condition.
Ankylosing spondylitis: May reduce inflammation, stiffness, and pain affecting the spine and other joints.
Plaque psoriasis: Helps manage moderate to severe disease in eligible patients.
Crohn's disease and ulcerative colitis: May help control inflammation in the digestive tract and reduce disease activity.
Hidradenitis suppurativa: May help reduce inflammatory skin lesions in eligible patients.
Juvenile idiopathic arthritis and uveitis: Certain forms of these conditions may also be treated with adalimumab, depending on age, diagnosis, and product approval.
The approved indications differ by country and product. A healthcare professional determines whether adalimumab is appropriate based on the patient's condition and treatment history.
Before starting adalimumab, healthcare professionals generally review the patient's medical history, current medications, infection risks, and previous treatments. Screening and ongoing monitoring are important because the medicine changes how parts of the immune system function.
Patients should follow their prescribed dosing schedule and discuss concerns with their healthcare team rather than adjusting treatment independently.
Infection risk: Adalimumab can increase the risk of serious infections, including tuberculosis and certain fungal infections. Screening for tuberculosis and assessment for other infections are important before treatment.
Possible side effects: Injection-site reactions, headaches, and upper respiratory infections can occur. Serious infections and other significant adverse effects require prompt medical assessment.
Vaccinations: Live vaccines are generally avoided during treatment. Patients should discuss vaccination timing with their healthcare professional.
Medical history: A history of tuberculosis, hepatitis B, heart failure, certain neurological disorders, or cancer may affect treatment decisions and monitoring requirements.
Pregnancy and breastfeeding: Patients who are pregnant, planning pregnancy, or breastfeeding should discuss potential benefits and risks with their healthcare professional.
Ongoing monitoring: Follow-up appointments help assess treatment response, identify adverse effects, and determine whether the treatment plan needs adjustment.
Patients should seek urgent medical attention for symptoms that may indicate a serious infection or severe allergic reaction. Treatment decisions should always be individualized, and prescribed medication should not be stopped or changed without medical guidance unless emergency instructions indicate otherwise.
Adalimumab can provide meaningful disease control for eligible patients, but its suitability depends on individual circumstances. Understanding its approved uses, potential risks, and monitoring requirements supports informed discussions with healthcare professionals.